Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient ...

Agios Pharmaceuticals Inc. AGIO stock is trading lower after the update on the sickle cell disease program. The company ...

The biotech firm said it will discontinue development of its therapy for sickle cell disease following the outcome of a Phase ...

Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in ...

The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s ...

A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase (PK) activator has failed to support continued ...

Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a ...

The company is trying again after receiving a complete response letter from the FDA last year requested more data.

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

Agios stock jumps after the FDA accepts and grants priority review to its sNDA for mitapivat in sickle cell disease, with a ...

Agios Pharmaceuticals shares rose Tuesday after the U.S. Food and Drug Administration granted priority review to the company's supplemental new drug application for mitapivat to treat sickle cell ...

FDA's PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIR ...